Estrogen receptor (ER) and Progesterone receptor (PR) (ER/PR)

The Estrogen Receptor (ER) and Progesterone Receptor (PR) are ligand-activated nuclear transcription factors that mediate the physiological effects of steroid hormones. They are critical for the regulation of the female reproductive cycle, bone metabolism, and the development of secondary sexual characteristics (UniProt, 2024). Ethinyl estradiol is a potent synthetic estrogen that primarily targets ERα and ERβ; it is frequently combined with progestins (which target PR) in pharmacological preparations such as combined oral contraceptives (PubChem, 2024). This combination therapy works by suppressing the hypothalamic-pituitary-ovarian axis, thereby inhibiting the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) required for ovulation (StatPearls, 2023). Additionally, these receptors are significant in oncology, as their expression levels in breast and endometrial tissues are used to guide endocrine therapy and predict patient prognosis (National Cancer Institute, 2024). While ethinyl estradiol itself does not directly bind the Progesterone Receptor, its clinical use is almost inextricably linked to PR modulation via the progestin component of combined hormonal therapies. Safety concerns associated with targeting these receptors include an increased risk of venous thromboembolism and certain hormone-sensitive cancers.

Other names

ESR1ESR2PGRNR3A1NR3C3Nuclear receptor subfamily 3 group A member 1Nuclear receptor subfamily 3 group C member 3ER-alphaER-betaPR-APR-B

Ethinyl estradiol acts as a potent agonist of the Estrogen Receptor (ER), while the progestin component of combination therapies targets the Progesterone Receptor (PR). Their combined action suppresses the hypothalamic-pituitary-ovarian axis, inhibiting the secretion of GnRH, LH, and FSH, which prevents ovulation and alters the cervical mucus and endometrium to inhibit pregnancy (StatPearls, 2023; PubChem, 2024).